Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Pesquisa Study Connect
  • NCT02823574

Recruiting

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - CA209-714

Atualizado:   |   ClinicalTrials.gov

Imprima o Resumo

CONSIDERANDO ESTE ESTUDO?
Imprima esta página e o guia de estudo para ajudá-lo a conversar com seu médico.
Use o guia de estudo para navegar no processo de participação em um estudo clínico. Entenda os principais fatores a serem considerados antes de decidir e faça perguntas para sua equipe de saúde.
Imprimir esta página CA209-714
Baixar o guia

SELECIONAR IDIOMA

Detalhes do estudo

  • Phase 2

    Fase

  • Gênero(s)

  • 18+

    Faixa etária

  • Recruiting

Opções de tratamento

Braços de tratamento do Estudo
INTERVENÇÃO ATRIBUÍDA
Experimental: Nivolumab and Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Active Comparator: Nivolumab and Ipilimumab-placebo
Other: Placebo Biological: Nivolumab

Principais critérios de elegibilidade

For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Confirmed squamous cell head and neck cancer - Widespread (metastatic) disease, or returned after previous treatment (recurrent) - Tumor sample must be available for analysis of PDL1 (Programmed death-ligand 1) and HPV [Human Papilloma Virus (oropharynx only)] - Performance status ECOG 0-1 (Eastern Cooperative Oncology Group) Exclusion Criteria: - Previous treatment for metastatic or recurrent disease - Cancer arising from one of the following primary sites: paranasal sinus, nasopharynx, salivary gland, skin - Any non-squamous subtype - Active autoimmune disease - Positive test for hepatitis B, C or HIV (Human Immunodeficiency Virus) virus - Previous treatment with checkpoint inhibitor drugs - Active CNS metastases or carcinomatous meningitis Other protocol defined inclusion/exclusion criteria could apply

É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas

Tem dúvidas? Envie-nos um email.

Tem dúvidas?
Envie-nos um email.